BioSpace News Archive

Oncternal Therapeutics, Inc. announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

AVITA Medical, Inc. announced it has submitted its response to the U.S. Food and Drug Administration for additional information requested in connection to its premarket approval supplement for RECELL GO™.

Shattuck Labs, Inc. (Shattuck) today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent business highlights.

Seer, Inc., a leading life sciences company commercializing a disruptive new platform for proteomics, reported financial results for the fourth quarter and full year ended December 31, 2023.

Atrion Corporation announced its results for the fourth quarter ended December 31, 2023 and the full year 2023.

Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that it has commenced an underwritten public offering of its common stock.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today reported financial results for the quarter and full year ended December 31, 2023.

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from ongoing preclinical research on the topical administration of a formulation of Provectus’s proprietary, pharmaceutical-grade, small molecule, rose bengal sodium (“RBS”) drug substance are being presented at the annual meeting of the Society for Investigative Dermatology (“SID”), to be held May 15-18, 2024 in Dallas, Texas.